Plasma ctDNA enables early detection of temozolomide resistance mutations in glioma.

ABSTRACT:

Background

Liquid biopsy based on circulating tumor DNA (ctDNA) is a novel tool in clinical oncology, however, its use has been limited in glioma to date, due to low levels of ctDNA. In this study, we aimed to demonstrate that sequencing techniques optimized for liquid biopsy in glioma patients can detect ctDNA in plasma with high sensitivity and with potential clinical utility.

Methods

We investigated 10 glioma patients with tumor tissue available from at least 2 surgical operations, who had 49 longitudinally collected plasma samples available for analysis. Plasma samples were sequenced with CAPP-seq (AVENIO) and tissue samples with TSO500.

Results

Glioma-derived ctDNA mutations were detected in 93.8% of plasma samples. 25% of all mutations detected were observed in

SUBMITTER: Jones JJ 

PROVIDER: S-EPMC11003533 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature